Open AccessTalazoparib (Talzenna™)
Author(s) -
Heidi D. Finnes
Publication year - 2019
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000615180.46903.7f
Subject(s) - eribulin , vinorelbine , medicine , parp inhibitor , metastatic breast cancer , breast cancer , olaparib , brca mutation , clinical endpoint , oncology , chemotherapy , gemcitabine , cancer , clinical trial , poly adp ribose polymerase , polymerase , biology , genetics , cisplatin , gene